Drug Trial Radar · NCT02859961
Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection
Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
562
Actual
Start
Dec 7, 2016
Primary completion
Sep 16, 2020
Study completion Dec 7, 2020
Sponsor
- Lead sponsor
- CytoDyn, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 9, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 2b/3, multi-center study designed to evaluate the efficacy, safety, and tolerability of the strategy of shifting clinically stable patients receiving suppressive combination antiretroviral therapy to PRO 140 monotherapy and maintaining viral suppression for 48 weeks following study entry. Consenting patients will be shifted from combination antiretroviral regimen to weekly PRO 140 monotherapy for 48 weeks during the Treatment Phase with the one week overlap of existing retroviral regimen and PRO 140 at the beginning of the study treatment and also one week overlap at the end of the treatment in subjects who do not experience virologic failure.
Conditions
- HIV
Interventions
PRO 140 (350 mg)Drug
PRO 140 350 mg (175 mg/mL) SC injection per week
PRO 140 (525 mg)Drug
PRO 140 525 mg (175 mg/mL) SC injection per week
PRO 140 (700 mg)Drug
PRO 140 700 mg (175 mg/mL) SC injection per week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic FailureTime frame: From T1 (first treatment administration) to week 48 (T48).
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
CD03 Investigational site
La Mesa, California
CD03 Investigational site
Palm Springs, California
CD03 Investigational site
San Francisco, California
CD03 Investigational site
New Haven, Connecticut
CD03 Investigational site
Norwalk, Connecticut
CD03 Investigational site
Ft. Pierce, Florida
CD03 Investigational site
Orlando, Florida
CD03 Investigational site
West Palm Beach, Florida
CD03 Investigational site
Wichita, Kansas
CD03 Investigational site
Las Vegas, Nevada
CD03 Investigational site
New York, New York
CD03 Investigational site
Syracuse, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.